<DOC>
	<DOCNO>NCT02725918</DOCNO>
	<brief_summary>The study prospective , multi-center , open-label , randomize , control phase II clinical trial . The investigator hope figure well chemotherapy regimen post-EGFR-TKI failure setting . The primary objective trial compare progression-free survival without grade 4 ( G4PFS ) toxicities pemetrexed-cisplatin single-agent pemetrexed treatment arm . The trial include stage IIIB/IV EGFR mutation positive NSCLC patient get disease progression front-line EGFR TKI treatment.Eligible patient randomize 2 arm . Patients arm A receive 4 cycle cisplatin ( 75 mg/m2 , d1 ) pemetrexed ( 500 mg/m2 , d1 ) every 3 week , without disease progression ( PD ) tolerable judge investigator continue single-agent pemetrexed ( 500 mg/m2 , d1 ) every 3 week maintenance progression intolerable toxicity . Patients arm B receive pemetrexed ( 500 mg/m2 , d1 ) every 3 week PD intolerable toxicity .</brief_summary>
	<brief_title>Pemetrexed v Pemetrexed Plus Cisplatin Epidermal Growth Factor Receptor ( EGFR ) -Mutant NSCLC Patients After First Line EGFR Tyrosine Kinase Inhibitors ( TKIs ) Failure</brief_title>
	<detailed_description>The study prospective , multi-center , open-label , randomize , control phase II clinical trial . The trial include stage IIIB/IV EGFR activate mutation positive NSCLC patient get disease progression frontline EGFR-TKI treatment . Clinical staging determine accord routine protocol , include enhanced chest CT scan , abdominal ultrasonography CT scan , brain MRI CT , bone scintigraphy . Positron emission tomography ( PET ) /CT scan optional . Measurement acquire resistance EGFR-TKIs base Jackman criterion . Eligible patient randomize 2 arm . Patients arm A receive 4 cycle cisplatin ( 75 mg/m2 , d1 ) pemetrexed ( 500 mg/m2 , d1 ) every 3 week , without disease progression ( PD ) tolerable judge investigator continue single-agent pemetrexed ( 500 mg/m2 , d1 ) every 3 week maintenance progression intolerable toxicity . Patients arm B receive pemetrexed ( 500 mg/m2 , d1 ) every 3 week PD intolerable toxicity . All patient administrate vitamin B12 folic acid supplement ( vitamin B12 1mg intramuscular injection least 7 day prior first dose pemetrexed repeat approximately every 9 week pemetrexed treatment till 22 day last dose pemetrexed ; folic acid 0.5 mg orally administer daily least 7 day prior first dose pemetrexed till 22 day last dose pemetrexed ) . Efficacy data analyze intention-to-treat ( ITT ) population use randomized patient , safety data evaluate use CTCAE v4.0 criterion patient receive ≥ 1 dose study treatment . If criteria drug administration ( absolute neutrophil count ≥1500/μl , platelets ≥100 000/μl , creatinine clearance ≥45 ml/min , grade ≥3 nonhematologic toxicity [ except alopecia ] ) meet , drug administration delay allow sufficient time recovery . If delay 42 day due toxicity necessary , patient discontinue study . Dose adjustment accord hematologic toxicity start subsequent cycle therapy base platelet neutrophil nadir count precede cycle . Granulocyte colony-stimulating factor allow use neutropenia event . Patients discontinue study treatment follow reason : disease progression ; unacceptable toxicity ; patient 's refusal continue . Radiological examination ( accord RECIST 1.1 criterion ) baseline repeat tumor response evaluation follow every two cycle chemotherapy . Patients follow 30 day last dose study chemotherapy , every 3 month . Blood sample [ 8ml ehylene diamine tetraacetic acid ( EDTA ) anticoagulant time ] collect time baseline , tumor response evaluation every 2 cycle , disease progression . Blood sample baseline disease progression mandatory provide . Tumor sample collection time baseline and/or disease progression strongly recommend mandatory study .</detailed_description>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<mesh_term>Pemetrexed</mesh_term>
	<criteria>1 . Informed consent must sign . 2 . Age ≥18 &lt; 75 year old . 3 . Performance status ( PS ) 0 2 Eastern Cooperative Oncology Group ( ECOG ) Scale . 4 . Histologically confirm stage IIIB/IV advance NSCLC harbor activate EGFR mutation . 5 . Chemotherapynaïve advance disease . 6 . Acquired resistance measure accord Jackman criterion . Achieved complete remission ( CR ) /partial remission ( PR ) ≥4 month stable disease ( SD ) ＞6 month firstline EGFR TKIs ( Gefitinib Erlotinib Icotinib ) advance NSCLC . 7 . Disease progression ( RECIST ) ＜4 week prior study randomization . 8 . Adequate organ function include follow : Bone marrow : absolute neutrophil count ( ANC ) ≥1.5 x 109/L , platelet ≥100 x 109/L hemoglobin ≥9 g/dL . Hepatic : total bilirubin ≤1.5 time upper limit normal ( ULN ) , liver transaminase : aspartate transaminase ( AST SGOT ) alanine transaminase ( ALT SGPT ) ≤2.5 time ULN . AST ALT ≤ 5 x ULN may include Patient liver metastasis . Renal : calculated creatinine clearance ≥45 mL/min ( use standard CockcroftGault formula ) . 9 . Patients resolution &lt; Grade 2 CTCAE ( Version 4.0 ) , clinically significant toxic effect prior anticancer therapy ( exception rash alopecia ) . 10 . Patients stable central nervous system ( CNS ) metastasis successfully treat local therapy , asymptomatic CNS metastasis eligible . Treated stable CNS metastasis allow ; patient must stable radiotherapy ≥2 week corticosteroid ≥1 week . 11 . At least one measurable lesion define RECIST 1.1 criterion . 12 . Previous palliative radiation therapy allow , limited &lt; 25 % bone marrow must include whole pelvis radiation . Patients must recover toxic effect treatment prior study enrollment ( except alopecia ) . Prior radiotherapy must complete one month study entry . Radiotherapy administer target lesion select study , unless progression select target lesion within radiation portal document . 13 . Estimated life expectancy least 8 week . 14 . For woman : must surgically sterile , postmenopausal , compliant highly effective contraceptive method 3 month treatment period ; must pregnant must lactate ; negative pregnancy test require woman childbearing potential . Postmenopausal woman must amenorrhoeic least 12 month consider nonchildbearing potential . For men : must surgically sterile compliant highly effective contraceptive method 3 month treatment period . 15 . Patient compliance geographic proximity allow adequate followup . Willingness provide blood sample EGFR mutation test baseline disease progression . 1 . Patient get disease relapse within 12 month postoperative adjuvant chemotherapy , thereafter get failure subsequent EGFRTKI treatment enrol . 2 . History another malignancy within last 5 year except cured carcinoma insitu uterine cervix , cure basal cell carcinoma skin superficial bladder tumor [ Ta , Tis &amp; T1 ] . 3 . Any unstable systemic disease ( include active infection , hepatic , renal metabolic disease ) serious concomitant disorder compromise safety patient , compromise patient 's ability complete study , discretion investigator . 4 . Significant cardiovascular event : congestive heart failure &gt; New York Heart Association ( NYHA ) class 2 ; unstable angina , active coronary artery disease ( myocardial infarction 1 year prior study entry allow ) ; serious cardiac arrhythmia require antiarrythmic therapy ( beta blocker digoxin permit ) uncontrolled hypertension . 5 . History significant neurological mental disorder , include seizure dementia . 6 . Incision operation heal start study treatment ( Small incision biopsy eligible . ) 7 . Presence clinically uncontrollable thirdspace fluid collection , example , ascites pleural effusion control drainage procedure prior study entry . 8 . Inability unwillingness interrupt aspirin nonsteroidal antiinflammatory drug ( NSAIDs ) 2 day 2 day administration pemetrexed . If patient take NSAID ( include Cox2 inhibitor ) salicylate long halflife ( e.g . naproxen , piroxicam , diflusinal , nabumetone , rofecoxib , celecoxib ) , take 5 day 2 day administration pemetrexed . 9 . Inability unwillingness take folic acid , vitamin B12 supplementation , dexamethasone . 10 . Inability comply protocol study procedure . 11 . Concurrent use antitumor therapy study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>March 2016</verification_date>
	<keyword>NSCLC</keyword>
	<keyword>EGFR-TKI failure</keyword>
	<keyword>chemotherapy</keyword>
</DOC>